Financial Year 2025 – First Half Results

Cyclopharm FY2025 Half-Year Results — Investor Presentation Highlights.

Join Cyclopharm CEO James McBrayer and CFO Jason Smith as they provide a detailed update on the company’s commercial progress, financial performance, and global expansion efforts for the first half of FY2025. In this investor presentation, Mr McBrayer outlines milestones in the U.S. launch of Technegas®, emerging clinical applications beyond pulmonary embolism, and the company’s strong financial position as it scales up operations.

Presentation overview:

• U.S. market update and commercial rollout progress
• Technegas® superiority and adoption trends globally
• Major U.S. contracts signed (VA, DoD, hospital networks)
• Expanding clinical indications (asthma, COPD, transplant)
• Financial highlights and cash position
• Investor FAQs addressed (installations, competitive landscape, revenue timing)